pancreatic cancer
Conditions
Interventions
novel peptide cocktail vaccine 1mL will be administered by subcutaneous injection on days, 1,8,15 and 22 of each 28-day treatment cycles.
Sponsors
Second Department of Surgery, Wakayama Medical University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Locally advanced or metastatic pancreatic ductal carcinoma histologically confirmed as adenocarcinoma or squamous cell carcinoma. 2)no prior chemotherapy and radiotherapy 3)KPS score>=80 4)HLA-A*24 or HLA-A*02 must be positive 5)Life Expectancy must be >=3 months 6)Adequate organ functions 7)The written consent form
Exclusion criteria
Exclusion criteria: 1)History of other active malignancy 2)Pancreatic cancer infiltrated into digestive tract with serious concern of bleeding 3)Interstitial pneumonia or pulmonary fibrosis 4)Brain metastasis or symptoms of it 5)Pleural effusion, ascites, and pericardial fluid requiring drainage 6)Active infections 7)Severe nervous disorder or mental disorder 8)Severe organ disorder, equivalent to CTCAE grade3 or greater 9)History of ischemic heart disease, cerebral infarction, or thromboembolism within 12 months 10)Evidence of bleeding diathesis or severe coagulopthy, or patients with those histories 11)Need continuous medication of anticoagulant drug except aspirin 12)Pregnant females or nursing mothers who can not stop lactation after the recruitment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Countries
Japan
Contacts
Public ContactMotoki Miyazawa
Wakayama Medical University, School of Medicine Second Department of Surgery
Outcome results
None listed